دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Incidence and Outcomes of Pneumonia in Patients With Heart Failure
LiShenMBChB, PhDabPardeep S.JhundMBChB, MSc, PhDbInder S.AnandMD, DPhilcAnkeet S.BhattMD, MBAdAkshay S.DesaiMD, MPHdAldo P.MaggioniMDeFelipe A.MartinezMDfMarc A.PfefferMD, PhDdAdel R.RizkalaPharmDgJean L.RouleauMDhKarlSwedbergMD, PhDiMuthiahVaduganathanMD, MPHdOrlyVardenyPharmDjDirk J.van VeldhuisenMDkFaiezZannadMD, PhDlMichael R.ZileMDmMiltonPackerMDnScott D.SolomonMDdJohn J.V.McMurrayMDb
doi : 10.1016/j.jacc.2021.03.001
Volume 77, Issue 16, 27 April 2021, Pages 1961-1973
The incidence of pneumonia and subsequent outcomes has not been compared in patients with heart failure and reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
Impact of Pneumonia in Heart Failure Patients?
DonnaManciniMDGregory T.GibsonMD
doi : 10.1016/j.jacc.2021.03.010
Volume 77, Issue 16, 27 April 2021, Pages 1974-1976
Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events
Adam P.BressPharmD, MSaTomGreenePhDaCatherine G.DeringtonPharmD, MSaJinchengShenPhDaYizheXuPhDaYiyiZhangPhDbJianYingPhDcBrandon K.BellowsPharmD, MSbWilliam C.CushmanMDdePaul K.WheltonMDfNicholas M.PajewskiPhDgDavidReboussinPhDgSrinivasanBeddhuMDhRachelHessMD, MSaJennifer S.HerrickMSaZuguiZhangPhDiPaulKolmPhDjRobert W.YehMDk…Andrew E.MoranMD, MPHb
doi : 10.1016/j.jacc.2021.02.058
Volume 77, Issue 16, 27 April 2021, Pages 1977-1990
Intensive systolic blood pressure (SBP) treatment prevents cardiovascular disease (CVD) events in patients with high CVD risk on average, though benefits likely vary among patients.
Another Nudge to Overcome the Treatment-Risk Paradox in Blood Pressure Management?
Joseph A.DiamondMDaAdam E.SchussheimMDbRobert A.PhillipsMD, PhDcd
doi : 10.1016/j.jacc.2021.03.230
Volume 77, Issue 16, 27 April 2021, Pages 1991-1993
Initial Findings From the North American COVID-19 Myocardial Infarction Registry
SantiagoGarciaMDaPayamDehghaniMDbCindyGrinesMDcdLauraDavidsonMDeKeshav R.NayakMDfJacquelineSawMDgRonWaksmanMDhJohnBlairMDiBagaiAkshayMDjRossGarberichMS, MBAaChristianSchmidtMSaHung Q.LyMD, SMkScottSharkeyMDaNestorMercadoMDlCarlos E.AlfonsoMDmNaokiMisumidaMDnDeepakAcharyaMDoMinaMadanMDpAbdul MoizHafizMDqNosheenJavedMDrJayShavadiaMDsJayStoneMDtM. ChadiAlraiesMDuWahHtunMDvWilliamDowneyMDwBrian A.BergmarkMDxJospehEbingerMDyTareqAlyousefMDzHoumanKhaliliMDaaChao-WeiHwangMD, PhDbbccJoshuaPurowMDddAlexanderLlanosMDddBrentMcGrathMDeeMarkTannenbaumMDffJonResarMDggRodrigoBagurMDhhPedroCox-AlomarMDiiAda C.Stefanescu SchmidtMD, MScjjLindsey A.CiliaMDjjFarouc A.JafferMD, PhDjjMichaelGharacholouMDkkMichaelSalingerMDllBrianCaseMDhAmeerKabourMDmmXumingDaiMDnnOsamaElkhateebMDooTaiseiKobayashiMDppHahn-HoKimMDqqMazenRoumiaMDrrFrank V.AguirreMDssJeffreyRadeMDttAun-YeongChongMDuuHurst M.HallMDvvShyAmlaniMDwwAlirezaBagherliMDxxRajan A.G.PatelMDyyDavid A.WoodMDzzFrederick G.WeltMDaaabbbJayGiriMD, MPHppEhtishamMahmudMDcccTimothy D.HenryMDdddon behalf of theSociety for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council
doi : 10.1016/j.jacc.2021.02.055
Volume 77, Issue 16, 27 April 2021, Pages 1994-2003
The coronavirus disease 2019 (COVID-19) pandemic has impacted many aspects of ST-segment elevation myocardial infarction (STEMI) care, including timely access to primary percutaneous coronary intervention (PPCI).
The Clinical Challenge of ST-Segment Elevation Myocardial Infarction and COVID-19?
RanKornowskiMDKatiaOrvinMD
doi : 10.1016/j.jacc.2021.03.231
Volume 77, Issue 16, 27 April 2021, Pages 2004-2006
Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya
RajeshVedanthanMDaJemima H.KamanoMMedbcStavroula A.ChrysanthopoulouPhDdRichardMugoScMcBenjaminAndamaMAcGerald S.BloomfieldMDeCleophas W.ChesoliMAcAllison K.DeLongMSdDavidEdelmanMDeEric A.FinkelsteinPhDefCarol R.HorowitzMDgSimonManyaraBPharmcDianaMenyaMBChBhVioletNaanyuPhDiVitalisOrangoBScSonak D.PastakiaPhDjThomas W.ValentePhDkJoseph W.HoganScDd?ValentinFusterMDg?
doi : 10.1016/j.jacc.2021.03.002
Volume 77, Issue 16, 27 April 2021, Pages 2007-2018
Incorporating social determinants of health into care delivery for chronic diseases is a priority.
A Good Start to Lowering BP and CVD Risk in Sub-Saharan Africa?
Tazeen H.JafarMD, MPHaCatherineKyobutungiPhDb
doi : 10.1016/j.jacc.2021.03.013
Volume 77, Issue 16, 27 April 2021, Pages 2019-2021
Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review
HenriHonkaMD, PhDaCarolinaSolis-HerreraMDaCurtisTriplittPharmDaLukeNortonPhDaJavedButlerMDbRalph A.DeFronzoMDa
doi : 10.1016/j.jacc.2021.02.057
Volume 77, Issue 16, 27 April 2021, Pages 2022-2039
The mechanisms responsible for the positive and unexpected cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes remain to be defined. It is likely that some of the beneficial cardiac effects of these antidiabetic drugs are mediated, in part, by altered myocardial metabolism. Common cardiometabolic disorders, including the metabolic (insulin resistance) syndrome and type 2 diabetes, are associated with altered substrate utilization and energy transduction by the myocardium, predisposing to the development of heart disease. Thus, the failing heart is characterized by a substrate shift toward glycolysis and ketone oxidation in an attempt to meet the high energetic demand of the constantly contracting heart. This review examines the metabolic pathways and clinical implications of myocardial substrate utilization in the normal heart and in cardiometabolic disorders, and discusses mechanisms by which antidiabetic drugs and metabolic interventions improve cardiac function in the failing heart.
NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review
William M.OldhamMD, PhDa?Anna R.HemnesMDb?Micheala A.AldredPhDcJohnBarnardPhDdEvan L.BrittainMD, MSbStephen Y.ChanMD, PhDeFeixiongChengPhDdMichael H.ChoMD, MPHaAnkit A.DesaiMDcJoe G.N.GarciaMDfMark W.GeraciMDgSusan D.GhiassianPhDhKathryn T.HallPhD, MPHaEvelyn M.HornMDiMohitJainMD, PhDjRachel S.KellyPhD, MPHaJane A.LeopoldMDaSaraLindstromPhDk…LeiXiaoMD, PhDq
doi : 10.1016/j.jacc.2021.02.056
Volume 77, Issue 16, 27 April 2021, Pages 2040-2052
The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease.
2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)
Writing Committee MembersBiykemBozkurtMD, PhD, FACC, FAHA(Co-Chair)Ray E.HershbergerMD, FACC, FAHA(Co-Chair)JavedButlerMBBS, MPH, MBA, FACC, FAHAKathleen L.GradyPhD, FAHAPaul A.HeidenreichMD, FACC, FAHAMaria LizzaIslerMSHIAJames K.KirklinMD, FACCWilliam S.WeintraubMD, MACC, FAHA?
doi : 10.1016/j.jacc.2020.11.012
Volume 77, Issue 16, 27 April 2021, Pages 2053-2150
ACC: Finding Our Strengths, Being Innovative, Unifying Our Global Cardiovascular Community
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.03.296
Volume 77, Issue 16, 27 April 2021, Pages 2151-2153
Papillary Fibroelastoma Growth: A Retrospective Follow-Up Study of Patients With Pathology-Proven Papillary Fibroelastoma
Reto D.KurmannMDEdward A.El-AmMDAhmed A.SorourMDAliAhmadMDAlexander T.LeeBSChristopher G.ScottMSMelanie C.BoisMDJoseph J.MaleszewskiMDKyle W.KlarichMD
doi : 10.1016/j.jacc.2021.02.027
Volume 77, Issue 16, 27 April 2021, Pages 2154-2155
Simultaneous Transcatheter Aortic Valve Replacement and Endovascular Aortic Aneurysm Repair
HalimYammineMDCharles S.BriggsMDQuantel V.RolleMDJocelyn K.BallastBAJohn R.FrederickMDEricSkipperMDWilliamDowneyMDMichael J.RinaldiMDMarkus D.SchererMDFrank R.ArkoIIIMD
doi : 10.1016/j.jacc.2021.02.059
Volume 77, Issue 16, 27 April 2021, Pages 2156-2157
Magnetic Resonance for Risk Stratification of Coronary Artery Disease Patients: Toward an Electrophysiology-Guided Approach?
Athanasios A.KordalisMD, PhDKonstantinos A.GatzoulisMD, PhDPetros P.ArsenosMD, PhDDimitris L.TsiachrisMD, PhDCostas P.TsioufisMD, PhD
doi : 10.1016/j.jacc.2021.02.052
Volume 77, Issue 16, 27 April 2021, Page 2157
Reply: Magnetic Resonance for Risk Stratification of Coronary Artery Disease Patients: Toward an Electrophysiology-Guided Approach?
FranciscoLeyvaMDBertholdStegemannPhDTianQiuPhD
doi : 10.1016/j.jacc.2021.02.051
Volume 77, Issue 16, 27 April 2021, Page 2158
